Chimerix, Inc. , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the final study design for the Phase 3 SUPPRESS trial of CMX001 in the prevention of cytomegalovirus infection following an allogeneic hematopoietic stem cell transplant .
http://www.drugs.com/clinical_trials/chimerix-announces-final-study-design-phase-3-suppress-trial-cmx001-prevention-cmv-infection-15457.html
http://www.drugs.com/clinical_trials/chimerix-announces-final-study-design-phase-3-suppress-trial-cmx001-prevention-cmv-infection-15457.html
No comments:
Post a Comment